– Using Invitae's Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare cancer to drive further research – – ...

Invitae (OTC:NVTA), backed by Softbank (OTCPK:SFTBY) and Cathie Wood's Ark Investment Management, filed for Chapter 11 bankruptcy protection, to address the genetic-testing company's more than $1B ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...

Genetic testing company Invitae has made more than a dozen acquisitions to further its goal of democratizing genetic testing. Its latest deal, a $325 million bid to acquire Ciitizen, will add patients ...

Invitae (NVTA) has become a favorite of ARK Investment Management, a famous Tesla bull in the electric vehicle manufacturer's early days. In fact, the investment firm's CEO, Cathie Wood, has called ...

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

Medical genetics company Invitae is partnering with research program Simons Searchlight to analyze rare genetic neurodevelopmental disorders through data sharing. Invitae will share its longitudinal ...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious ...

Spotlight Top Pick InVitae Corp (NYSE:NVTA) has seen its stock decline and one culprit was a recently published article “How a cancer test maker started by former Twitter, Google execs hopes to change ...

Invitae, a San Francisco-based genetic tech company, announced it is laying off more than 700 employees at its headquarters. The layoffs at Invitae are part of a larger corporate restructuring in ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that the company now offers a new Breast Cancer STAT Panel of high-quality genetic ...

Bull case: Invitae has launched a plan to reach positive cash flow as soon as possible. Any progress could drive share gains. Bear case: Invitae comes with too much risk in an uncertain market. Could ...